Tatiana Kniazeva
Charles Stark Draper Laboratory
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Tatiana Kniazeva.
Biomedical Microdevices | 2011
Tatiana Kniazeva; James C. Hsiao; Joseph L. Charest; Jeffrey T. Borenstein
One of the principal challenges in artificial lung technology has been the ability to provide levels of oxygen and carbon dioxide exchange that rival those of the natural human lung, while mitigating the deleterious interaction between blood and the surface of the synthetic gas exchange membrane. This interaction is exacerbated by the large oxygenator surface area required to achieve sufficient levels of gas transfer. In an effort to address this challenge, microfluidics-based artificial lung technologies comprising stacked microchannel networks have been explored by several groups. Here we report the design, fabrication and initial testing of a parallel plate multilayered silicone-based microfluidic construct containing ultrathin gas exchange membranes, aimed at maximizing gas transfer efficiency while minimizing membrane-blood contact area. The device comprises a branched microvascular network that provides controlled wall shear stress and uniform blood flow, and is designed to minimize blood damage, thrombosis and inflammatory responses seen in current oxygenators. Initial testing indicates that flow distribution through the multilayer structure is uniform and that the thin membrane can withstand pressures equivalent to those expected during operation. Oxygen transfer using phosphate buffered saline as the carrier fluid has also been assessed, demonstrating a sharp increase in oxygen transfer as membrane thickness is reduced, consistent with the expected values of oxygen permeance for thin silicone membranes.
Lab on a Chip | 2012
Tatiana Kniazeva; Alla Epshteyn; James C. Hsiao; Ernest S. Kim; Vijaya Kolachalama; Joseph L. Charest; Jeffrey T. Borenstein
Microfluidic fabrication technologies are emerging as viable platforms for extracorporeal lung assist devices and oxygenators for cardiac surgical support and critical care medicine, based in part on their ability to more closely mimic the architecture of the human vasculature than existing technologies. In comparison with current hollow fiber oxygenator technologies, microfluidic systems have more physiologically-representative blood flow paths, smaller cross section blood conduits and thinner gas transfer membranes. These features can enable smaller device sizes and a reduced blood volume in the oxygenator, enhanced gas transfer efficiencies, and may also reduce the tendency for clotting in the system. Several critical issues need to be addressed in order to advance this technology from its current state and implement it in an organ-scale device for clinical use. Here we report on the design, fabrication and characterization of multilayer microfluidic oxygenators, investigating scaling effects associated with fluid mechanical resistance, oxygen transfer efficiencies, and other parameters in multilayer devices. Important parameters such as the fluidic resistance of interconnects are shown to become more predominant as devices are scaled towards many layers, while other effects such as membrane distensibility become less significant. The present study also probes the relationship between blood channel depth and membrane thickness on oxygen transfer, as well as the rate of oxygen transfer on the number of layers in the device. These results contribute to our understanding of the complexity involved in designing three-dimensional microfluidic oxygenators for clinical applications.
Biomicrofluidics | 2016
David M. Hoganson; Eric B. Finkelstein; Gwen E. Owens; James C. Hsiao; Kurt Y. Eng; Katherine M. Kulig; Ernest S. Kim; Tatiana Kniazeva; Irina Pomerantseva; Craig M. Neville; James R. Turk; Bernard Fermini; Jeffrey T. Borenstein; Joseph P. Vacanti
In pre-clinical safety studies, drug-induced vascular injury (DIVI) is defined as an adverse response to a drug characterized by degenerative and hyperplastic changes of endothelial cells and vascular smooth muscle cells. Inflammation may also be seen, along with extravasation of red blood cells into the smooth muscle layer (i.e., hemorrhage). Drugs that cause DIVI are often discontinued from development after considerable cost has occurred. An in vitro vascular model has been developed using endothelial and smooth muscle cells in co-culture across a porous membrane mimicking the internal elastic lamina. Arterial flow rates of perfusion media within the endothelial chamber of the model induce physiologic endothelial cell alignment. Pilot testing with a drug known to cause DIVI induced extravasation of red blood cells into the smooth muscle layer in all devices with no extravasation seen in control devices. This engineered vascular model offers the potential to evaluate candidate drugs for DIVI early in the discovery process. The physiologic flow within the co-culture model also makes it candidate for a wide variety of vascular biology investigations.
Advanced Healthcare Materials | 2012
Leon M. Bellan; Tatiana Kniazeva; Ernest S. Kim; Alla Epshteyn; Donald M. Cropek; Robert Langer; Jeffrey T. Borenstein
Archive | 2011
Jeffrey T. Borenstein; Joseph L. Charest; James C. Hsiao; Tatiana Kniazeva
Archive | 2012
Jeffrey T. Borenstein; Joseph L. Charest; James C. Hsiao; Tatiana Kniazeva; Ernest S. Kim; Alla Epshteyn; Vijaya Kolachalama
PMC | 2012
Leon M. Bellan; Tatiana Kniazeva; Ernest S. Kim; Alla Epshteyn; Donald M. Cropek; Robert Langer; Jeffrey T. Borenstein
Archive | 2012
Jeffrey T. Borenstein; Joseph L. Charest; James C. Hsiao; Tatiana Kniazeva; Ernest S. Kim; Alla Epshteyn; Vijaya Kolachalama
Archive | 2012
Jeffrey T. Borenstein; Joseph L. Charest; James C. Hsiao; Tatiana Kniazeva; Ernest S. Kim; Alla Epshteyn; Vijaya Kolachalama
Advanced Healthcare Materials | 2012
Leon M. Bellan; Tatiana Kniazeva; Ernest S. Kim; Alla Epshteyn; Donald M. Cropek; Robert Langer; Jeffrey T. Borenstein